Reinovax Biologics

Shanghai Reinovax Biologics Co., Ltd. was established in September 2017 as a high-tech biopharmaceutical company based on independent research and development, founded by senior returned experts. The company focuses on the research and production of high-quality, internationally advanced biotechnological products.The company’s R&D center is located in Shanghai Zhangjiang Science City, a cluster hub representing international advanced levels in the biomedical industry. The company currently operates an advanced bioproducts R&D platform with GMP-level pilot production capabilities, along with a Class 10,000 cleanroom, Biosafety Level 2 laboratory. Meanwhile, the company has cultivated a professional and dedicated team to carry out research in genetic engineering, fermentation, purification, conjugation, immunology, clinical medicine, quality analysis, and control, effectively advancing the discovery, preclinical R&D, pilot-scale process optimization, and clinical studies of novel vaccines, antibodies, and recombinant protein-based drugs.In May 2020, Shanghai Reinovax Biologics Co., Ltd. established Changchun Reinovax Biopharmaceutical Co., Ltd. in Changchun, Jilin Province, to transform its R&D achievements into vaccine products, creating an international-standard vaccine GMP manufacturing and R&D base. Changchun Reinovax is located in the Biomedical Industrial Park of Changchun's High-Tech Industrial Development Zone, covering an area of approximately 78,700 square meters with a total construction area of nearly 115,000 square meters. The company will build modern production workshops, formulation workshops, storage centers, R&D and quality control centers, animal testing facilities, a comprehensive office building, and other supporting infrastructure that meet EU standards.